Liaosadat Mirsafaei

Mazandaran University of Medical Sciences

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Zatollah Asemi

Kashan University of Medical Sciences

Jamal Hallajzadeh

University of Maragheh

ŽR

Željko Reiner

University Hospital Centre Zagreb

Fatemeh Sadoughi

Kashan University of Medical Sciences

Mohammad Alì Mansournia

Tehran University of Medical Sciences

Bahman Yousefi

Tabriz University of Medical Sciences

Rana Shafabakhsh

RWTH Aachen University

Hassan Vahidnezhad

University of Pennsylvania

Parisa Maleki Dana

Kashan University of Medical Sciences

Elaheh Amirani

Kashan University of Medical Sciences

Cooperative Institutions

Tehran University of Medical Sciences

Kashan University of Medical Sciences

Shahid Beheshti University of Medical Sciences

Thomas Jefferson University

Jefferson Institute

University of Tehran

Iran University of Medical Sciences

Sidney Kimmel Cancer Center

Tabriz University of Medical Sciences

University of Zagreb

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

The effect of nutraceuticals on multiple signaling pathways in cardiac fibrosis injury and repair

Heart Failure Reviews (2020)

Parinaz Zivarpour Željko Reiner Jamal Hallajzadeh Liaosadat Mirsafaei Zatollah Asemi

Cardiac Fibrosis

Nutraceutical

10.1007/s10741-020-09980-6

Cite

Citations (1)

Molecular and Biological Functions of Quercetin as a Natural Solution for Cardiovascular Disease Prevention and Treatment

Plant Foods for Human Nutrition (2020)

Liaosadat Mirsafaei Željko Reiner Rana Shafabakhsh Zatollah Asemi

Dyslipidemia

10.1007/s11130-020-00832-0

Cite

Citations (48)

The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials

Clinical Nutrition ESPEN (2020)

Omid Asbaghi Niloofar Ghanbari Mahdi Shekari Željko Reiner Elaheh Amirani

10.1016/j.clnesp.2020.04.010

Cite

Citations (25)

Arrhythmogenic right ventricular cardiomyopathy in patients with biallelic JUP-associated skin fragility

Scientific Reports (2020)

Hassan Vahidnezhad Leila Youssefian Masoomeh Faghankhani Nikoo Mozafari Amir Hossein Saeidian

Abstract Arrhythmogenic right ventricular cardiomyopathy (ARVC), with skin manifestations, has been associated with mutations in JUP encoding plakoglobin. Genotype–phenotype correlations regarding the penetrance of cardiac involvement, and age of onset have not been well established. We examined a cohort of 362 families with skin fragility to screen for genetic mutations with next-generation sequencing-based methods. In two unrelated families, a previously unreported biallelic mutation, JUP : c.201delC; p.Ser68Alafs * 92, was disclosed. The consequences of this mutation were determined by expression profiling both at tissue and ultrastructural levels, and the patients were evaluated by cardiac and cutaneous work-up. Whole-transcriptome sequencing by RNA-Seq revealed JUP as the most down-regulated gene among 21 skin fragility-associated genes. Immunofluorescence showed the lack of plakoglobin in the epidermis. Two probands, 2.5 and 22-year-old, with the same homozygous mutation, allowed us to study the cross-sectional progression of cardiac involvements in relation to age. The older patient had anterior T wave inversions, prolonged terminal activation duration (TAD), and RV enlargement by echocardiogram, and together with JUP mutation met definite ARVC diagnosis. The younger patient had no evidence of cardiac disease, but met possible ARVC diagnosis with one major criterion (the JUP mutation). In conclusion, we identified the same biallelic homozygous JUP mutation in two unrelated families with skin fragility, but cardiac findings highlighted age-dependent penetrance of ARVC. Thus, young, phenotypically normal patients with biallelic JUP mutations should be monitored for development of ARVC.

Penetrance

Plakoglobin

Proband

Haploinsufficiency

10.1038/s41598-020-78344-9

Cite

Citations (12)

ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY IN PATIENTS WITH BI-ALLELIC JUPASSOCIATED SKIN FRAGILITY

Journal of the American College of Cardiology (2021)

Liaosadat Mirsafaei Hassan Vahidnezhad Leila Youssefian Jouni Uitto

10.1016/s0735-1097(21)01761-7

Cite

Citations (0)

Resveratrol and Cardiac Fibrosis Prevention and Treatment

Current Pharmaceutical Biotechnology (2021)

Parinaz Zivarpour Željko Reiner Jamal Hallajzadeh Liaosadat Mirsafaei

Cardiovascular diseases are some of the major causes of morbidity and mortality in developed and developing countries. Cardiac fibrosis is one of the most often pathological changes of heart tissues. It occurs as a result of extracellular matrix proteins accumulation at myocardia. Cardiac fibrosis results in impaired cardiac systolic and diastolic functions and is associated with other effects. Therapies with medicines have not been sufficiently successful in treating chronic diseases such as CVD. Therefore, the interest for therapeutic potential of natural compounds and medicinal plants has increased. Plants such as grapes, berries and peanuts contain a polyphenolic compound called "resveratrol" which has been reported to have various therapeutic properties for a variety of diseases. Studies on laboratory models show that resveratrol has beneficial effects on cardiovascular diseases, including myocardial infarction, high blood pressure cardiomyopathy, thrombosis, cardiac fibrosis, and atherosclerosis. In vitro animal models using resveratrol indicated protective effects on the heart by neutralizing reactive oxygen species, preventing inflammation, increasing neoangiogenesis, dilating blood vessels, suppressing apoptosis and delaying atherosclerosis. In this review, we are presenting experimental and clinical results of studies concerning resveratrol effects on cardiac fibrosis as a CVD outcome in humans.

Cardiac Fibrosis

Myocardial fibrosis

10.2174/1389201022666210212125003

Cite

Citations (18)

mTOR pathway and DNA damage response: A therapeutic strategy in cancer therapy

DNA repair (2021)

Romina Danesh Pazhooh Parnia Rahnamay Farnood Zatollah Asemi Liaosadat Mirsafaei Bahman Yousefi

mTORC2

RPTOR

Ribosomal s6 kinase

Ribosomal protein s6

10.1016/j.dnarep.2021.103142

Cite

Citations (25)

Cardiac fibrosis and curcumin: a novel perspective on this natural medicine

Molecular Biology Reports (2021)

Fatemeh Sadoughi Jamal Hallajzadeh Liaosadat Mirsafaei Zatollah Asemi Mahdi Zahedi

Cardiac Fibrosis

Myocardial fibrosis

10.1007/s11033-021-06768-1

Cite

Citations (5)

The role of DNA damage response in chemo- and radio-resistance of cancer cells: Can DDR inhibitors sole the problem?

DNA repair (2021)

Fatemeh Sadoughi Liaosadat Mirsafaei Parisa Maleki Dana Jamal Hallajzadeh Zatollah Asemi

DNA Damage Repair

10.1016/j.dnarep.2021.103074

Cite

Citations (20)

Are anti-inflammatory agents and nutraceuticals - novel inhibitors of PCSK9?

Critical Reviews in Food Science and Nutrition (2020)

Rana Shafabakhsh Željko Reiner Jamal Hallajzadeh Liaosadat Mirsafaei Zatollah Asemi

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protease which increases the lysosomal degradation of low density lipoprotein receptor (LDLR) resulting in elevated serum LDL-cholesterol levels. Elevated LDL-cholesterol is the main risk factor for cardiovascular disease (CVD). Antibodies to PCSK9 decrease LDL-cholesterol. Recent studies have suggested a direct relationship between PCSK9 and inflammation and the potential inhibitory effects of anti-inflammatory agents against this enzyme. Nutraceuticals are natural compounds, which have numerous anti-inflammatory and lipid-lowering effects. In this review we focus on anti-inflammatory substances and nutraceuticals, which are beneficial in treatment of dyslipidemia. We also reviewed the recent findings concerning the role of PCSK9 as the main target for molecular mechanisms of these substances.

PCSK9

Nutraceutical

Kexin

Proprotein Convertases

Dyslipidemia

10.1080/10408398.2020.1731678

Cite

Citations (9)